| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net loss | -131,369 | -76,478 | -26,135 | -124,428 |
| Share-based compensation expense | 23,026 | 15,832 | 7,883 | 25,218 |
| Depreciation and amortization | 680 | 443 | 217 | 712 |
| Amortization of discount of marketable securities | 2,249 | 2,135 | 2,082 | - |
| Amortization of debt issuance costs and exit fee of long-term debt | 876 | 605 | 312 | - |
| Change in fair value of financial instruments | - | 0 | 0 | 0 |
| Change in deferred taxes | 2,276 | 2,021 | 995 | 2,255 |
| Tax incentive receivable | 3,535 | -6,448 | 4,283 | -5,494 |
| Prepaid expenses and other assets | 1,910 | -2,025 | 2,676 | -5,730 |
| Operating leases, net | 191 | 128 | 65 | 225 |
| Accounts payable | 1,362 | -1,918 | -2,095 | -4,728 |
| Accrued expenses and other liabilities | -27,358 | -26,669 | -29,550 | -9,963 |
| Other, net | 0 | - | 103 | 230 |
| Net cash used in operating activities | -138,010 | -79,698 | -57,246 | -99,255 |
| Purchases of investments in marketable securities | 426,049 | 380,537 | 297,476 | 140,533 |
| Proceeds from redemption of investments in marketable securities | 226,012 | 118,321 | 75,088 | 146,834 |
| Purchases of property and equipment | 360 | 126 | - | 34 |
| Net cash (used in) provided by investing activities | -200,397 | -262,342 | -222,388 | 6,267 |
| Proceeds from issuance of shares under atm program, net of issuance costs-Underwriter Offering | 0 | 0 | - | 349,980 |
| Proceeds from issuance of shares under atm program, net of issuance costs-At The Market Program | 6,109 | 6,109 | 6,109 | 9,655 |
| Proceeds from option exercises | 7,030 | 3,468 | 1,763 | 5,885 |
| Payment of employee withholding taxes related to withheld shares for stock based compensation plans | 4,615 | 4,490 | - | - |
| Other, net | -396 | -396 | -4,786 | -3,731 |
| Net cash provided by financing activities | 8,128 | 4,691 | 3,086 | 361,789 |
| Effect of exchange rate on cash and cash equivalents | -2,131 | -1,630 | -1,517 | -1,805 |
| Net decrease in cash and cash equivalents | -332,410 | -338,979 | -278,065 | 266,996 |
| Cash and cash equivalents at beginning of period | 383,221 | 383,221 | 383,221 | 128,030 |
| Cash and cash equivalents at end of period | 50,811 | 44,242 | 105,156 | 395,026 |
Centessa Pharmaceuticals plc (CNTA)
Centessa Pharmaceuticals plc (CNTA)